No Data
A-shares midday review: Chinext Price Index rises by 0.41%, flu Concept stocks are active, and the CSI Consumer 360 index sectors are experiencing a decline.
As of the midday break, the Shanghai Composite Index fell by 0.15% to 3206.75 points, the Shenzhen Component Index rose by 0.19%, and the Chinext Price Index increased by 0.41%.
A-share midday review: The Shanghai Composite Index fell by 0.46%. Resource stocks led the gains. The CSI Consumer 360 index underwent collective adjustment.
By midday, the Shanghai Composite Index fell by 0.46% to 3247.54 points, the Shenzhen Component Index declined by 0.23%, and the Chinext Price Index decreased by 0.28%.
The State Council meeting deployed to deepen the regulatory reform of Pharmaceutical and medical instruments, and Institutions indicated that there are significant structural opportunities in the Pharmaceutical Industry.
According to media reports, the recent State Council executive meeting deployed measures to deepen the regulation reform of pharmaceuticals and medical instruments, promoting the high-quality development of the pharmaceutical industry. Orient stated that looking back at 2024, the high base from the past has been digested, and the intra-hospital rigid demand is being released normally. Meanwhile, the Industry Chain of Innovative Drugs and the export of instruments continue to yield results, and the overall growth logic is clearly visible.
Lukang Pharma's Four Drugs Get Added to China's Centralized Procurement
Shandong Lukang Pharmaceutical (600789.SH): The company and its holding subsidiaries participate in the national pharmaceutical centralized procurement and are expected to win the bid.
On December 19, Gelonghui reported that Shandong Lukang Pharmaceutical (600789.SH) announced that the company and its controlling subsidiary, ShanDong Lukang Pharmaceutical Group Saiter Co., Ltd. (referred to as "Saiter Company"), participated in the bidding for the tenth nationwide centralized Pharmaceutical procurement organized by the Joint Procurement Office. The company and Saiter Company intend to have some of their Pharmaceuticals selected in this centralized procurement.
Is Shandong Lukang Pharmaceutical Co.,Ltd.'s (SHSE:600789) Latest Stock Performance A Reflection Of Its Financial Health?
Is The Market Rewarding Shandong Lukang Pharmaceutical Co.,Ltd. (SHSE:600789) With A Negative Sentiment As A Result Of Its Mixed Fundamentals?
